NCT03784885View on ClinicalTrials.gov

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

PHASE2CompletedINTERVENTIONAL

Enrollment

345

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

January 7, 2018

Study Completion Date

October 30, 2018

Conditions

Influenza Infection

Interventions

BIOLOGICAL

AD07010

A protein based adjuvant

BIOLOGICAL

Inactivated trivalent influenza vaccine

Inactivated trivalent seasonal influenza vaccine

Trial Locations (1)

104

Advagene Biopharma, Taipei

All Listed Sponsors

lead

Advagene Biopharma Co. Ltd.

INDUSTRY

NCT03784885 - A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult | Biotech Hunter | Biotech Hunter